questionText: To ask the Secretary of State for Health and Social Care, when he expects NICE to publish the outcomes of the appeals on its final draft guidance on donanemab and lecanemab.
answerText: The appeals against the National Institute for Health and Care Excellence (NICE) recommendations on donanemab and lecanemab for the treatment of Alzheimer’s disease were heard by NICE’s independent appeal panel in January. The next steps of the appraisal ...
heading: Donanemab and Lecanemab